---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-060129"
form_type: "8-K"
ticker: "ASCBF"
cik: "0001876716"
company_name: "ASPAC II Acquisition Corp."
filed_at: "2023-07-27T23:59:59+00:00"
generated_at: "2026-06-13T00:57:29.042879+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# A SPAC II identifies Taiwan medtech target for potential business combination

## Summary
- Target specializes in microsphere tech for ultrasound contrast agents and drug delivery.
- First product has passed review to enter Phase 3 trial application with USFDA.
- Special meeting on Aug 1, 2023 to vote on extension and other proposals.
- Company in preliminary talks to enter non-binding LOI with Partner.
- No guarantee definitive agreement will be reached; due diligence ongoing.

## SEC filing metadata
- accession: 0001213900-23-060129
- form_type: 8-K
- ticker: ASCBF
- cik: 0001876716
- company_name: ASPAC II Acquisition Corp.
- filed_at: 2023-07-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1876716/000121390023060129/0001213900-23-060129-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1876716/000121390023060129/ea182387-8k_aspac2.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-060129
- JSON: https://secwatch.observer/filing/0001213900-23-060129.json
- Plain text: https://secwatch.observer/filing/0001213900-23-060129.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.